Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
Status:
Recruiting
Trial end date:
2022-03-16
Target enrollment:
Participant gender:
Summary
Fecal microbiota transplantation (FMT) has been very effective for patients who suffer from
mild C diff infection (CDI) which recurs but it is unclear how effective FMT alone is in
treating severe and fulminant CDI. Current evidence suggests that FMT in combination with
vancomycin is required, and that multiple treatments are necessary. The investigators think
fidaxomicin may be a better option in the context and may potentially reduce the number of
FMT required. However, fidaxomicin has never been used to treat severe or fulminant CDI. In
this pilot study, the investigators plan to use a combination of FMT plus fidaxomicin to
determine efficacy and safety in treating patients with severe or fulminant CDI. The
investigators want to see if this approach may reduce the number of FMT treatment required,
and/or the length of hospital stay.